The Union Budget 2025-26 strengthens India's healthcare sector with an allocation of Rs. 99,858.56 crore, marking a 9.78% rise from Rs. 90,958.63 crore in 2024-25
Based on DESTINY-Breast06 Phase III trial results which showed Enhertu demonstrated superiority vs. chemotherapy with a median progression-free survival of more than one year
BRAFTOVI combination regimen is the first and only targeted therapy approvedby the U.S. FDA for treatment-naïve patients with metastatic colorectal cancer with a BRAF V600E mutation
700 new scientific and high-skilled jobs to be created in Greater Toronto Area, investing to execute more than 210 AstraZeneca global clinical studies
Teriflunomide is a novel disease-modifying agent that was approved for use in the treatment of multiple sclerosis
The company is committed to unlocking new frontiers in neuroscience and developing Usnoflast for patients with ALS
Expand the scope of the Production-Linked Incentive (PLI) scheme and increase its allocation to cover more pharmaceutical products and raw materials
_256_384.jpg)
Mesalazine is used to treat inflammatory bowel disease
This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo
Datroway is the eighth new medicine of the 20 AstraZeneca has set out to deliver by 2030
Subscribe To Our Newsletter & Stay Updated
